Defining the Immunotherapy Impact in Merkel Cell Carcinoma - prIME Oncology
Expert Review
Expert Review

Defining the Immunotherapy Impact in Merkel Cell Carcinoma

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

This Expert Review features internationally-renowned thought leaders discussing the latest data regarding the management of advanced Merkel cell carcinoma (MCC), including diagnostic and prognostic tools, the role of Merkel cell polyomavirus (MCPyV), and the current and emerging uses of checkpoint inhibitors for the treatment of MCC. This program also features a companion downloadable slide deck that includes key information covered in the discussion.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Oct 17, 2017

Expiration Date

Oct 17, 2018

  • Jürgen Becker, MD, PhDGerman Cancer Research Forum (DKTK)
    Medical University Hospital Essen
    Essen, Germany
  • Axel Hauschild MD, PhDUniversity of Kiel
    Schleswig-Holstein, Germany
  • Caroline Robert, MD, PhDGustave Roussy
    Villejuif, France
  • Brief overview of MCC
  • Clinical presentation, including diagnostic and prognostic tools
  • MCPyV role in treatment selection
  • Current and emerging uses of checkpoint inhibitors for MCC

This educational activity is specifically designed to meet the needs of healthcare providers involved in the therapeutic management of patients with Merkel cell carcinoma, including oncologists, dermatologists, surgeons, nurses, and researchers.

Upon completion of this educational activity, participants should be able to:

  • Describe MCC and currently available diagnostic and prognostic tools
  • Evaluate the role of MCPyV in guiding treatment selection for patients with MCC
  • Explain ongoing clinical trials of PD-1/PD-L1 inhibitors in comparison with already established treatment options for patients with MCC

This educational activity is supported by a grant from Merck KGaA and Pfizer.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.